


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-69. (canceled)

70. (New) A method for treating excessive osteolysis in a patient, comprising administering to said patient an effective amount of a compound of Formula I:



wherein

R is independently H, OH, alkyl, aryl, cycloalkyl, heteroaryl, alkoxy, heterocyclic and amino;

each R₁ is independently selected from the group consisting of alkyl, halo, aryl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heteroaryl, heterocyclic, hydroxy, -C(O)-R₈, -NR₉R₁₀, -NR₉C(O)-R₁₂ and -C(O)NR₉R₁₀;

each R₂ is independently selected from the group consisting of alkyl, aryl, heteroaryl, -C(O)-R₈ and SO₂R'', where R'' is alkyl, aryl, heteroaryl, NR₉N₁₀ or alkoxy;

each R₅ is independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, cycloalkyl, heteroaryl, heterocyclic, hydroxy, -C(O)-R₈ and (CHR)_rR₁₁;

X is O or S;

p is 0-3;

q is 0-2;


r is 0-3;

R₈ is selected from the group consisting of -OH, alkyl, aryl, heteroaryl, alkoxy, cycloalkyl and heterocyclic;

R₉ and R₁₀ are independently selected from the group consisting of H, alkyl, aryl, aminoalkyl, heteroaryl, cycloalkyl and heterocyclic, or R₉ and R₁₀ together with N may form a ring, where the ring atoms are selected from the group consisting of C, N, O and S;

R_{11} is selected from the group consisting of $-OH$, amino, monosubstituted amino, disubstituted amino, alkyl, aryl, heteroaryl, alkoxy, cycloalkyl and heterocyclic; R_{12} is selected from the group consisting of alkyl, aryl, heteroaryl, alkoxy, cycloalkyl and heterocyclic;

$R_{12,s}$ selected from the group consisting of alkyl, aryl, heteroaryl, alkoxy, cycloalkyl and heterocyclic; Z is OH , O -alkyl, or $-NR_3R_4$, where R_3 and R_4 are independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, and heterocyclic, or R_3 and R_4 may combine with N to form a ring where the ring atoms are selected from the group consisting of CH_2 , N , O and S or



wherein Y is independently CH_2 , O , N or S ,

Q is C or N ;

n is independently $0-4$; and

m is $0-3$;


or a salt thereof,

wherein said compound or salt inhibits phosphorylation of colony stimulating factor 1 receptor (CSF1R).

71. (New) The method of claim 70, wherein R_1 is halo and p is 1.

72. (New) The method of claim 70, where Z is $-NR_3R_4$, wherein R_3 and R_4 form a morpholine ring.

73. (New) The method of claim 70, wherein Z is;




wherein each Y is CH_2 , each n is 2, m is 0 and R_3 and R_4 form a morpholine ring.

74. (New) The method of claim 70, wherein R_2 is methyl and q is 2, wherein the methyls are bonded at the 3 and 5 positions.


75. (New) The method of claim 70, wherein R_5 is H .

76. (New) The method of any of claims 70-75, wherein r is 0.

77. (New) The method of claim 70, wherein the compound administered is selected from the group consisting of



78. (New) The method of claim 70, wherein the compound of formula I is selected from the group consisting of:



79. (New) The method of claim 70, wherein the patient has cancer that has metastasized to bone.

80. (New) The method of claim 70, wherein the patient has cancer that secretes macrophage colony stimulating factor (M-CSF).

81. (New) The method of claim 70, wherein the patient has osteoporosis.

82. (New) The method of claim 70, wherein the patient is post-menopausal.